Expand BLTE Menu
BLTE MENU

BLTE Latest Press Releases

-- August 12, 2026 --

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update Globe Newswire 9:45 PM

-- August 11, 2026 --

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 4:01 PM

-- August 6, 2026 --

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- July 20, 2026 --

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 Globe Newswire 8:00 AM

-- July 15, 2026 --

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference Globe Newswire 8:00 AM

-- July 6, 2026 --

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium Globe Newswire 8:00 AM
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences Globe Newswire 7:00 AM

-- June 12, 2026 --

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Globe Newswire 9:30 PM

-- June 2, 2026 --

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Globe Newswire 8:00 AM

-- May 20, 2026 --

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update Globe Newswire 6:00 AM

-- May 18, 2026 --

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland Globe Newswire 4:00 PM

-- May 15, 2026 --

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) Globe Newswire 8:00 AM

-- May 13, 2026 --

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results Globe Newswire 4:00 PM

-- April 29, 2026 --

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing Globe Newswire 8:44 AM

-- April 27, 2026 --

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit Globe Newswire 8:00 AM

-- April 23, 2026 --

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026 Globe Newswire 8:35 AM
Belite Bio to Participate in Four Upcoming Investor Conferences Globe Newswire 8:00 AM

-- April 22, 2026 --

Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th Globe Newswire 8:35 AM

-- April 21, 2026 --

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Globe Newswire 4:00 PM

-- March 31, 2026 --

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes